11/15/2026

Janusmed amning

Janusmed amning – tofacitinibcitrat

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
3 3
3 3

Tofacitinib

Tofacitinib

Klass : 3

Visa all info

Skriv ut

Kontakta oss

  1. Julsgaard M, Mahadevan U, Vestergaard T, Mols R, Ferrante M, Augustijns P. Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis. Lancet Gastroenterol Hepatol. 2023;8(8):695-697.

  2. Mitrova K, Julsgaard M, Augustijns P, Cerna K, Mahadevan U, Duricova D et al. Tofacitinib in Pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood, and Breast Milk Concentrations. Clin Gastroenterol Hepatol. 2025;23(1):163-165e3.

  3. Ernest-Suarez K, Murguía-Favela LE, Novak KL, Panaccione R, Constantinescu C, Seow CH. Normal Infant Immunologic Assessment and Uneventful Live Rotavirus Vaccination Despite Continuous Tofacitinib Exposure In Utero and During Breastfeeding. Crohns Colitis 360. 2024;6(1):otae006.

  4. Mitrova K, Kostrejova M, Zdychyncova K, Lukas M, Duricova D. Effect of tofacitinib exposure in utero and during breastfeeding on the immune status of exposed child. J Crohns Colitis. 2025;19(4).

  5. Alajlan A, Alshehri NA, Alfouzan S, Barakeh M, Alangari S, Alsuwaidan S. Tofacitinib exposure across 2 pregnancies in alopecia universalis: Case report and literature review of Janus kinase inhibitors in pregnancy. JAAD Case Rep. 2026;6(74):129-135.

  1. Julsgaard M, Mahadevan U, Vestergaard T, Mols R, Ferrante M, Augustijns P. Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis. Lancet Gastroenterol Hepatol. 2023;8(8):695-697.
  2. Mitrova K, Julsgaard M, Augustijns P, Cerna K, Mahadevan U, Duricova D et al. Tofacitinib in Pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood, and Breast Milk Concentrations. Clin Gastroenterol Hepatol. 2025;23(1):163-165e3.
  3. Ernest-Suarez K, Murguía-Favela LE, Novak KL, Panaccione R, Constantinescu C, Seow CH. Normal Infant Immunologic Assessment and Uneventful Live Rotavirus Vaccination Despite Continuous Tofacitinib Exposure In Utero and During Breastfeeding. Crohns Colitis 360. 2024;6(1):otae006.
  4. Mitrova K, Kostrejova M, Zdychyncova K, Lukas M, Duricova D. Effect of tofacitinib exposure in utero and during breastfeeding on the immune status of exposed child. J Crohns Colitis. 2025;19(4).
  5. Alajlan A, Alshehri NA, Alfouzan S, Barakeh M, Alangari S, Alsuwaidan S. Tofacitinib exposure across 2 pregnancies in alopecia universalis: Case report and literature review of Janus kinase inhibitors in pregnancy. JAAD Case Rep. 2026;6(74):129-135.

Innehållet senast uppdaterat 11/3/2026